Výsledky vyhledávání

P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study

Autor: A Buisson, A Jammet, B Pereira, M Fumery

Publikováno v: Journal of Crohn's and Colitis. 17:i562-i564

Background While surgery was considered as the reference for stricturing Crohn's disease (CD), anti-TNF agents are now the first-line treatment thanks to the CREOLE study. However, there is no efficacy data after anti-TNF failure. We aimed to compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c5b31cd937076b887d13fefc6d6173b
https://doi.org/10.1093/ecco-jcc/jjac190.0565

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

Autor: A Buisson, M Serrero, R Altwegg, T Guilmoteau, G Bouguen, M Nachury, A Amiot, L Vuitton, X Treton, L Caillo, B Pereira, M Fumery

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement_1), pp.i707-i707. ⟨10.1093/ecco-jcc/jjac190.0709⟩

Background We aimed to compare the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent. Methods In this multicenter study, we retrospectively included consecutive UC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffb7d754eb5a4a75892bacb4ceef6c4
https://u-picardie.hal.science/hal-04161046

Zobrazit plný text záznamu

P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease

Autor: C Yzet, F Brazier, V Hautefeuille, L Grados, C Decrombecque, M Diouf, M Fumery

Publikováno v: Journal of Crohn's and Colitis. 17:i475-i476

Background Crohn's disease (CD) is associated with disability by affecting physical and emotional well-being, and by altering social interactions. In the era of treat to target, endoscopic remission has become the therapeutic target to prevent pariet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e903dc8605182b4b4b73690f2ca54a6
https://doi.org/10.1093/ecco-jcc/jjac190.0468

Zobrazit plný text záznamu

DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE

Autor: K Matsuoka, M Löwenberg, M Fumery, Y Takatori, Y Fujitani, A Oortwijn, M Faes, C Jamoul, T Hibi

Publikováno v: Journal of Crohn's and Colitis. 17:i112-i113

Background Filgotinib (FIL) is a once-daily, oral, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC) in Europe and Japan. Previous analyses of the SELECTION programme showed that, in patients with moderately

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f0aab00bfe64a0f003ac983a12da4b1
https://doi.org/10.1093/ecco-jcc/jjac190.0085

Zobrazit plný text záznamu

P299 Disability in newly diagnosed patients with Crohn′s Disease: initial results from the prospective CROCO (Crohn′s Disease Cohort) Study

Publikováno v: Journal of Crohn's and Colitis. 17:i443-i444

Background CD is classically seen as a progressive disease leading to bowel damage and disability. Disability has been proposed by the Spirit-IOIBD consensus1 as an endpoint in disease modification trials. However, there is a paucity of data regardin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::302e4e8028250c73ebf281eb7b39b10a
https://doi.org/10.1093/ecco-jcc/jjac190.0429

Zobrazit plný text záznamu

P303 Ultrasound is effective to identify mucosal healing in Crohn's disease patients : results of a cross-sectional study

Autor: C Yzet, F Brazier, V Hautefeuille, C Decrombecque, R Sarba, P aygalenq, F Venezia, A Buisson, R Pichois, A Michaud, M Fumery

Publikováno v: Journal of Crohn's and Colitis. 17:i448-i449

Background Endoscopy is still the gold-standard to assess disease activity in Crohn's disease (CD). Its invasiveness, acceptability and cost limit its use in the era of tight control and treat-to-target. Fecal calprotectin and intestinal ultrasound (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae8f9792bb8cabaf63efd4ea7ad31398
https://doi.org/10.1093/ecco-jcc/jjac190.0433

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání